Discover the newest additions to the HTRF® and Alpha portfolio
Feb 04, 2022
4 min
Cisbio launched several new target assays this week to further your research and drug discovery efforts. Learn more about the latest products and content.
Highlights:
Introduction of TYK2 kits in HTRF® format to complement the HTRF JAK1, JAK2, JAK3 kits
New AlphaLISA® C1q binding kit to support biologics development and characterization, in addition to our existing HTRF C1q assay
Additions to our E3 ligase portfolio to include HTRF VHL binding kits, AlphaLISA XIAP BIR2 binding kits, and XIAP BIR3 binding kits
Explore this all-encompassing guide on the pathogenesis of neurodegenerative diseases, including the involvement of neuroinflammation and glial cells. Find key disease facts and background, in-depth molecular pathways, and more!
Lugege põletikulisele soolehaigusele (IBD) suunatud tipptasemel ravimiuuringute kohta ja erinevatest uuringuetappidest, kus on kasutatud homogeenseid HTRF® ja AlphaLISA® teste.
Identifying PROTAC Compounds
Enhance your PROTAC drug discovery efforts with this application note featuring experiments targeting Bruton Tyrosine Kinase (BTK). Discover the information needed to be successful in your research, including assay principles, materials and methods, and results.
A Unique Approach to GPCR Research
The most studied regulators of GPCRs are orthosteric ligands, leaving allosteric ligands a mystery. Researchers at the University of Montpellier recently conducted studies indicating that allosteric modulators of GCPRs hold promise for drug discovery. Learn more in this blog post.
